Resectable Non-small Lung Cancer
Conditions
Brief summary
With the recent approval of Nivolumab for second-line treatment of stage IIIb/IV non-small cell lung cancer (NSCLC), immune checkpoint inhibitors are entering the standard of care for lung cancer. Other immune checkpoint inhibitors are under evaluation, both in resectable and non-resectable NSCLC. In order to refine our use of these molecules, comprehensive data on the immune contexture of NSCLC are needed. Moreover,a blood marker of this contexture would allow physicians to monitor the immune status of their patient's tumor and though to evaluate the rightful place of immunotherapy in the multimodal treatment of NSCLC. No such blood marker has been validated so far. The LYMPHOLUNG study investigate the concordance between blood and intratumoral counts of immune cells in resectable stage I to IIIA NSCLC. By the use of 30-marker cytometry, a precise immune profile of NSCLC will be depicted. The prognostic value of the circulating and intra-tumoral T regulator over total lymphocytes ratio for 2-year recurrence-free survival will also be addressed.
Interventions
PROCEDUREblood drawn
blood drawn
PROCEDUREsurgical resection of cancer
Sponsors
University Hospital, Rouen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women over 18 years of age * Histologically- or cytologically- confirmed non-small cell lung cancer diagnostic * Stage I, II or IIIA NSCLC (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology). Staging must have included an abdominal and thoracic CTscan, a CTscan or MRI of the brain and a 18FDG PETscan * Subjects for whom a surgical resection is indicated * Signed written informed consent
Exclusion criteria
* \- previous, ongoing or planned neo-adjuvant treatment (chemotherapy, targeted therapy, immunotherapy or radiotherapy) * contraindications to general anesthesia * contraindication to the planned surgical resection * history of immunosuppressive disorder * known history of testing positive for human immunodeficiency virus * subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 30 days of randomization. * clinical suspicion of active infection (either acute or chronic) * severe (hemoglobin \< 8.0 g/dL) or symptomatic anemia * women of childbearing potential must have a negative urine pregnancy test * women must not be breastfeeding * prisoners or subjects who are involuntarily incarcerated * subjects under guardianship
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of expression of the T regulator over total lymphocytes count ratio in the blood | Day 1 |
| Level of expression of the T regulator over total lymphocytes count ratio into the tumor | Day 1 |
Secondary
| Measure | Time frame |
|---|---|
| Number of cell population counts as blood markers for the corresponding population in the tumor | Day 1 |
| Number of patient alive 2 years after resection | 2 years |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORBérengère OBSTOY
University Hospital, Rouen
Outcome results
None listed